Biocon Biologics, a fully integrated global biosimilars company, has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access in India. This partnership aims to broaden access to Biocon Biologics’ portfolio of Metabolics, Oncology, Nephrology, Dermatology, and Critical Care products in India.
This collaboration aligns with Biocon Biologics’ strategy to enhance patient access to its world-class branded formulations in India, a franchise developed over the past two decades, by significantly leveraging Eris’ strong commercial footprint.
All Biocon Biologics’ products in India are now being commercialized by Eris Lifesciences.
